The ATLAS ACS-TIMI 46 Study Group investigators reported today in The Lancet that among patients with acute coronary syndromes, the use of oral rivaroxaban therapy was associated with a reduction in rates of major adverse events as well as with a dose-dependent increase in rates of clinically significant bleeding. Two candidate doses were associated with a reduction in the risk of death, MI and stroke, and these two low doses will now be studied in a large event driven phase III trial (ATLAS ACS II-TIMI 51).
<googlenewsdynamic sites="wsj.com:nytimes.com:geekdoctor.blogspot.com:news-medical.net" numresults="10">newstitle=Today in Medicine</googlenewsdynamic>
Cookies help us deliver our services. By using our services, you agree to our use of cookies.